Drugmaker AstraZeneca's earnings fall, hit by patent expiries

AstraZeneca's underlying earnings fell 12 percent in the first quarter, broadly in line with analyst expectations, hit by drug patent expiries. Revenue at the British drug company rose 1 percent in dollar ...